Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 8, Issue 5, 2013, Pages 599-605

  Gwak, Ho Shin ^a   Joo, Jungnam ^a   Kim, Sohee ^a   Yoo, Heon ^a   Shin, Sang Hoon ^a   Han, Ji Youn ^a   Kim, Heung Tae ^a   Lee, Jin Soo ^a   Lee, Seung Hoon ^a  

^a National Cancer Center   (South Korea)

Author keywords

Chemotherapy; Intraventricular; Leptomeningeal carcinomatosis; Non small cell lung cancer; Survival

Indexed keywords

CYTARABINE; ERLOTINIB; GEFITINIB; HYDROCORTISONE; METHOTREXATE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CAUDA EQUINA SYNDROME; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CRANIAL NEUROPATHY; CYTOLOGY; FEMALE; GROUPS BY AGE; HEADACHE; HUMAN; INTRACRANIAL PRESSURE; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; VOMITING;

EID: 84876420549     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318287c943     Document Type: Article

References (31)

1. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004;22(14):2865-72.
2. Fox BD, Cheung VJ, Patel AJ, et al. Epidemiology of metastatic brain tumors. Neurosurg Clin N Am 2011;22(1):1-6, v.
3. Chamberlain MC, Kormanik P. Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 1998;55:506-512.
4. Morris PG, Reiner AS, Szenberg OR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012;7:382-385.
5. Park JH, Kim YJ, Lee JO, et al. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 2012;76:387-392.
6. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fuid after intravenous, ventricular and lumbar injections. N Engl J Med 1975;293:161-166.
7. Wasserstrom WR, Glass J P, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982;49:759-772.
8. Ongerboer de Visser B W, Somers R, Nooyen WH, et al. Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 1983;33(12):1565-72.
9. Chamberlain MC, Kormanik PA, Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997;87:694-699.
10. Waki F, Ando M, Takashima A, et al. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol 2009;93:205-212.
11. Taillibert S, Laigle-Donadey F, Chodkiewicz C, et al. Leptomeningeal metastases from solid malignancy: a review. J Neurooncol 2005;75(1):85-99.
12. Chamberlain MC. Leptomeningeal metastasis. Curr Opin Oncol 2010;22: 627-635.
13. Herrlinger U, Förschler H, Küker W, et al. Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci 2004;223:167-178.
14. Gauthier H, Guilhaume MN, Bidard FC, et al. Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol 2010;21:2183-2187.
15. Seute T, Leffers P, Velde GPMt, et al. Leptomeningeal metastases from small cell lung carcinoma. Cancer 2005;104(8):1700-05.
16. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fuid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995;38:51-57.
17. Al-Anazi A, Bernstein M. Modifed stereotactic insertion of the Ommaya reservoir. Technical note. J Neurosurg 2000;92:1050-1052.
18. Gwak HS, Lee CH, Yang HS, et al. Chemoport with a non-collapsible chamber as a replacement for an Ommaya reservoir in the treatment of leptomeningeal carcinomatosis. Acta Neurochir (Wien) 2011;153:1971-8; discussion 1978.
19. Chamberlain MC. Leptomeningeal metastases: a review of evaluation and treatment. J Neurooncol 1998;37:271-284.
20. Bruna J, Gonzalez L, Miro J, et al. Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fuid features. Cancer 2009;115(2):381-9.
21. Masuda T, Hattori N, Hamada A, et al. Erlotinib effcacy and cerebrospinal fuid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during geftinib therapy. Cancer Chemother Pharmacol 2011;67:1465-1469.
22. Clarke JL, Pao W, Wu N, et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010;99(2):283-6.
23. Katayama T, Shimizu J, Suda K, et al. Effcacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to geftinib. J Thorac Oncol 2009;4:1415-1419.
24. Yi HG, Kim HJ, Kim YJ, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 2009;65:80-84.
25. Hitchins RN, Bell DR, Woods RL, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987;5(10):1655-62.
26. Chamberlain MC, Kormanik PA. Prognostic signifcance of 111indium-DTPA CSF fow studies in leptomeningeal metastases. Neurology 1996;46:1674-1677.
27. Chamberlain MC. Radioisotope CSF fow studies in leptomeningeal metastases. J Neurooncol 1998;38:135-140.
28. Bleyer WA, Poplack DG, Simon RM. "Concentration x time" methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 1978;51:835-842.
29. Nakagawa H, Fujita T, Kubo S, et al. Ventriculolumbar perfusion chemotherapy with methotrexate and cytosine arabinoside for meningeal carcinomatosis: a pilot study in 13 patients. Surg Neurol 1996;45:256-264.
30. Grossman SA, Trump DL, Chen DC, et al. Cerebrospinal fuid fow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Am J Med 1982;73(5):641-7.
31. Blasberg RG, Patlak CS, Shapiro WR. Distribution of methotrexate in the cerebrospinal fuid and brain after intraventricular administration. Cancer Treat Rep 1977;61:633-641.